Clinical trials: Psychotic Disorder
Hyperactive Delirium, Mixed Delirium
Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
Delirium is the most often encountered psychiatric diagnosis in the general hospital, with incidence up to 85% in the intensive care unit (ICU) setting and with significant consequences on patients' morbidity and mortality.
- Trial name
- NCT02343575
- Testing
- Valproic Acid, Haloperidol
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Stanford University
Psychotic Disorder
Peer Support for Exercise in Older Veterans With Psychotic Disorders
Older adults with psychotic disorders experience a dual set of challenges: those related to serious mental illness, and those related to aging.
- Trial name
- NCT02958007
- Testing
- Peer Education on Exercise for Recovery, Enhanced supervised fitness training
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
Aripiprazole in Adolescents With Schizophrenia
The purpose of this trial is to test the safety and efficacy of aripiprazole in adolescent patients with schizophrenia for a period of at least 6 weeks.
- Trial name
- APEX 239 (NCT00102063)
- Testing
- Aripiprazole tablet, 10 mg, Aripiprazole tablet, 30 mg
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 302 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
- Trial name
- NCT03568500
- Testing
- Digital Medicine System, Aripiprazole, Olanzapine
- Where
- 5 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?
Individuals with schizophrenia have been found to have deficits in social cognition, which is defined as the functions that are engaged during social interactions.
- Trial name
- NCT01312272
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Schizophrenia
Effects of Galantamine on Cognition
Schizophrenia is a chronic disorder with onset of psychosis occurring in late teen early twenties, with cognitive impairments and negative symptoms frequently emerging much earlier.
- Trial name
- NCT01100775
- Testing
- Galantamine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizo-affective Disorder
Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
The study will be a 6-month, open-label, multiple center study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone…
- Trial name
- NCT02658357
- Testing
- Risperidone Implant
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Braeburn Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial
Purpose: To test the effectiveness of an exercise intervention that combines group walking, activity tracking, and heart rate monitoring (i.e.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorders
- Trial name
- (PACE-life (NCT04173572)
- Testing
- PACE-Life, Exercise Intervention
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to evaluate the efficacy and safety of long acting injectable (LAI) risperidone and oral risperidone treatment on participants with schizophrenia (psychiatric disorder with symptoms of emotional…
- Trial name
- NCT00992407
- Testing
- Risperidone long acting injectables, Risperidone tablets
- Where
- South Korea
- Volunteers
- 75 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia, Schizoaffective Disorder
Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study
The goal of this study is to use transcranial magnetic stimulation (TMS) to investigate the impact of modulating cerebellar activity on time perception, executive function, and mood and psychotic symptoms in psychosis patients…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder I
- Trial name
- NCT02642029
- Testing
- Excitatory TMS, Inhibitory TMS
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Schizophrenia, Schizoaffective Disorder
Schizophrenic Patients in Integrated Care
The purpose of the study is to investigate the well-being of schizophrenic patients treated with quetiapine XR combined with participation in the integrated care program compared to a treatment with quetiapine XR alone over a…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- CARE II (NCT00681629)
- Testing
- Quetiapine XR, Integrated Care Program (ICP)
- Where
- 8 sites in Germany
- Volunteers
- 7 people
- Sponsor
- AstraZeneca
Schizophrenia
Phase IIA Study in Patients With Schizophrenia
This study is designed to assess the effects of AZD 2624 in patients with schizophrenia
- Trial name
- NCT00686998
- Testing
- AZD2624, Olanzapine
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
Schizophrenia
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 3831 in subjects with schizophrenia.
- Trial name
- NCT02873208
- Testing
- ALKS 3831
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 266 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Schizoaffective Disorder
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
The purpose of this study is to evaluate the effectiveness, safety and tolerability of risperidone long-acting injection (LAI) versus oral antipsychotics in participants with recent onset psychosis (abnormal thinking and/or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT00246259
- Testing
- Risperidone long-acting injection (LAI), Oral Antipsychotic
- Where
- 11 sites in Canada
- Volunteers
- 77 people
- Sponsor
- Janssen-Ortho Inc., Canada
Schizophrenia
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
The purpose of the this trial is to evaluate the efficacy, safety, and tolerability of an intramuscular (IM) depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia The trial is designed into…
- Trial name
- ASPIRE (NCT00706654)
- Testing
- Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg
- Where
- 98 sites in United States, Austria and 13 more
- Volunteers
- 937 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Cognitive Effect on Schizophrenic Patients
Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia
This is a randomized, double-blind, active-controlled, 6 month study designed to evaluate the cognitive effects of treatment with CYP-1020 compared to risperidone.
- Trial name
- CLARITY (NCT01363349)
- Testing
- CYP-1020, Risperidone
- Where
- 39 sites in India, Moldova and 1 more
- Volunteers
- 269 people
- Sponsor
- BioLineRx, Ltd.
Schizophrenia, Medication Nonadherence
Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)
The proposed, three phase project will refine and test a first-ever care approach in SSA that combines LAI with a behavioral program specifically intended to promote medication adherence in chronic psychotic disorders (CPDs).
- Conditions
- Schizophrenia, Medication Nonadherence, Schizo Affective Disorder
- Trial name
- CAPACITY (NCT04327843)
- Testing
- Customized Adherence Enhancement, Haloperidol Decanoate
- Where
- Tanzania
- Volunteers
- 22 people
- Sponsor
- Case Western Reserve University
Schizophrenia, Bipolar I Disorder
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)
This study is an open label, sequential-group, two site, multiple dose escalating study of sublingual administered asenapine in a pediatric population with schizophrenia or bipolar I disorder; in one study cohort (3a)…
- Trial name
- NCT01206517
- Testing
- Asenapine 2.5 mg, Asenapine 5 mg, Asenapine 10 mg
- Volunteers
- 30 people
- Sponsor
- Organon and Co
Bipolar Disorder, Schizophrenia
Treatment of Mania Symptoms With Drug Therapy
This study will determine the effectiveness of three different drug therapies in treating the symptoms of mania.
- Trial name
- NCT00183443
- Testing
- Divalproex-extended release (DVP-ER), Lithium, Quetiapine
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Palo Alto Veterans Institute for Research